Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients

• Status: Recruiting
• Trial end date: 2025-06-15
• Target enrollment: 0
• Participant gender: All

Summary

When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are comparatively evaluated as secondary outcome.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RAPHAS

Criteria

Inclusion Criteria:

• Patients aged 19 - 65years with allergic rhinitis caused by the house dust mite antigen.

• ImmunoCAP® titer > 3.49 kUA/L for the house dust mite antigen.

• Determined to be suitable for clinical trials as a result of laboratory tests.

Exclusion Criteria:

• Patients with uncontrolled, severe, or moderate asthma according to the Global Initiative for Asthma (GINA) guidelines.

• In case of lactation or pregnancy.

• If an infectious disease that may affect this study is identified.

• Patients with a history of rhinology surgery within 6 months prior to the first administration of the clinical investigational drug.

• If the allergy skin prick test is negative for the house dust mite antigen.